Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin in Combination With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)

NCT01874054 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT01874054
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01874054 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin in Combination With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Lead sponsor
Seagen Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2013
Completion date
February 20, 2018
Enrollment
55 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin disease